Silo Pharma Inc. (NASDAQ: SILO) announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the company's common stock. The program allows purchases on the open market, through privately negotiated transactions, or otherwise, in compliance with Securities and Exchange Commission rules and applicable legal requirements. According to the company's quarterly report for the period ended Sept. 30, 2025, Silo Pharma reported 13,318,273 shares of common stock outstanding as of Nov. 13, 2025.
The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations. The program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at its discretion. Share repurchase programs are typically implemented when companies believe their stock is undervalued and represent a method to return capital to shareholders while potentially increasing earnings per share for remaining stockholders.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company with a therapeutic focus on addressing underserved conditions including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories.
The announcement of a share repurchase program is significant for investors as it often signals management's confidence in the company's financial health and future prospects. By reducing the number of outstanding shares, buyback programs can increase earnings per share and potentially support the stock price. For a developmental-stage biopharmaceutical company like Silo Pharma, this move suggests the company has sufficient capital to fund both its research initiatives and shareholder return programs.
The latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO. The full press release announcing the share repurchase program can be viewed at https://ibn.fm/gU3uZ. This development comes as the company continues to advance its therapeutic pipeline targeting significant unmet medical needs in psychiatric disorders and chronic pain conditions.
For investors, the $1 million repurchase authorization represents approximately 7.5% of the company's market capitalization based on recent trading prices, though the actual impact will depend on the timing and execution of purchases. The program's flexibility allows management to be opportunistic based on market conditions, potentially acquiring shares when they believe the stock represents the best value. This strategic move could help stabilize the stock during periods of market volatility while demonstrating confidence in the company's long-term trajectory.
